Beraprost Sodium for Chronic Diabetic Foot Ulcer: A Randomized Controlled Trial in Thammasat University Hospital

Abstract

Background: Chronic diabetic foot ulcer has a high rate of healing failure. Beraprost sodium, oral form of prostaglandin I 2 analogue, maybe used for increasing wound healing. Objective: To compare the healing rate of chronic diabetic foot ulcer between Beraprost sodium and control groups. Design: A single blind randomized trial. Materials and Methods: Fifty non-healed chronic diabetic foot ulcer patients were randomized to be the study and control groups. Beraprost sodium was prescribed in the study group according to protocol. Results: At 6th week follow up, median wound healing rate in the study group was significantly higher than in the control group with the rate of 88.1% and 33.3%, respectively. Complete wound healing in the study group was also significantly higher than in the control group (48%:8%). In the study group, 9 patients (37.5%) could be administered with recommended dose. Side effects were headache in 14 patients (58.3%) and palpitation in one patient (4.2%). One patient was discontinued for severe headache. Conclusions: The use of Beraprost sodium in chronic diabetic foot ulcer patients significantly increases the wound healing rate. Headache was the common side effect.

Ultrasonography evaluation on the protective effect of combination therapy of beraprost sodium and aspirin on arteries occlusion and stiffness in patients with type 2 diabetes mellitus - a prospective, randomized study

“…Recently, it was reported that BPS reduced lower limb ischemic symptoms and carotid intima-media thickness in patients with PAD [ 8 ]. It was also found that chronic diabetic foot ulcer patients experienced a significant increase in the wound healing rate after the administration of BPS, suggesting that BPS might be a potential treatment in treating peripheral circulatory disorders in patients with diabetes [ 9 ]. However, the exact effect of BPS on arterial calcification and occlusion of peripheral arteries, especially lower limb arteries in patients with T2DM has not yet been fully investigated.…”